Fundraising FoxRarecyte
Seattle, US · Delaware corporation · 6 known investors
Find your way into Rarecyte
Sign up to see every warm intro you have to Rarecyte
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Rarecyte team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
Board
Investors · 6
How we know: 5AM Ventures's portfolio page · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
How we know: Arboretum Ventures's portfolio page · a partner's Signal profile · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
How we know: F-Prime Capital's portfolio page · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
How we know: Telegraph Hill Partners's portfolio page · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$79.8M disclosed across 5 rounds · 2017–2023
▶$13.2MraisedJul 2023 · 19 investors · OtherRule 506(b)
- David KabakoffDirector
- Ronald SeubertDirector
- Robert WeisskoffDirector
- Daniel MarshakDirector
- Jan GarfinkleDirector
- Andrew SchwabDirector
- Stephen ReichenbachExecutive Officer
- Joseph J. Victor Jr.Executive Officer, Director
- Offering amount
- $35.7M
- Amount sold
- $13.2M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$24MraisedSep 2021 · 27 investors · OtherRule 506(b)
- Andrew SchwabDirector
- Jan GarfinkleDirector
- Daniel MarshakDirector
- Ronald SeubertDirector
- Robert WeisskoffDirector
- David KabakoffDirector
- Joseph J. Victor Jr.Executive Officer, Director
- Offering amount
- $24M
- Amount sold
- $24M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$22.2MraisedDec 2019 · OtherRule 506(b)
- Andrew SchwabDirector
- David KabakoffDirector
- Ronald SeubertDirector
- Jim CooperExecutive Officer
- Joseph J. Victor Jr.Executive Officer, Director
- Frank WitneyDirector
- Offering amount
- $22.2M
- Amount sold
- $22.2M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedMay 2018 · 1 investors · OtherRule 506(b)
- Brian DanielsDirector
- Eric KaldjianExecutive Officer
- Robert SheplerDirector
- Ronald SeubertExecutive Officer, Director, Promoter
- Joseph VictorExecutive Officer, Director
- Frank WitneyDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.4MraisedAug 2017 · 9 investors · OtherRule 506(b)
- Robert SheplerDirector
- Ronald SeubertExecutive Officer, Director, Promoter
- Evan CastigliaExecutive Officer
- Brian DanielsDirector
- Joseph VictorExecutive Officer, Director
- Frank WitneyDirector
- Eric KaldjianExecutive Officer
- Offering amount
- $16.3M
- Amount sold
- $15.4M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Rarecyte.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $223.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $598.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- Who are Rarecyte's investors?
- Rarecyte's investors include 5AM Ventures, Arboretum Ventures, F-Prime Capital, Telegraph Hill Partners, HealthQuest Capital, Sofinnova Ventures.
- How much funding has Rarecyte raised?
- Rarecyte has disclosed $79.8M raised across 5 rounds.
- Where is Rarecyte headquartered?
- Rarecyte is headquartered in Seattle, US.